Vinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo Slider

Among the engineered antibody fragments, the Single Chain Variable Fragment (scFv) is the most popular and one of the smallest recombinant format with an antigen-binding activity function and with the property to be easily manageable for immunological application.

The use of scFv in diagnostics and therapy provides several advantages over whole antibodies, especially in solid tumours therapy; in fact the speed of penetration by a fragment versus an intact molecule is the most remarkable advantages.

In the Italian Patent IT1367861 is described a hybridoma cell line clone, named A7, able to secrete an anti-hERG1 monoclonal antibody (mAb) specific against the S5-pore extracellular portion of hERG1.

In November 2015, DI.V.A.L. TOSCANA obtained the licensing for the exploitation of the patent “hERG1 and Glut1 in colorectal cancer” (FI2011A000181; PCT/EP2012/065661; US 14/238486). The present invention describes the determination of the prognostic impact of hERG1 potassium channels along with other hypoxia-related biomolecular parameters, in patients who underwent radical surgery with curative intent for non metastatic colorectal cancer.

From November 2016, DI.V.A.L. TOSCANA got the licensing for the exclusive economic exploitation of the patent “anti-hERG1 molecules” (FI2014A000189; PCT/EP2015/068178). It describes the detailed structure of an intact murine monoclonal antihERG1 molecule and the corresponding anti-hERG1 scFv antibody production, obtained after the isolation of the mAb anti-hERG1 VH and VL. Such scFv has the same specificity of the correspondent whole antibody, and thus it is able to recognize the same hERG1 protein, aberrantly expressed in tumours and other diseases.

Furthermore,within the framework of the research projects in which it is involved, DI.V.A.L. TOSCANA is developing new products (GluR4-directed monoclonal antibodies, scFV anti-GluR4, scFV-cys) which can be used for research purposes and and as improved diagnostic tools for different pathologies. New patents are planned in 2017.